Cover Image
市場調查報告書

非小細胞肺癌 (NSCLC):開發中產品分析

Non-Small Cell Lung Cancer - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 232838
出版日期 內容資訊 英文 3034 Pages
訂單完成後即時交付
價格
Back to Top
非小細胞肺癌 (NSCLC):開發中產品分析 Non-Small Cell Lung Cancer - Pipeline Review, H1 2018
出版日期: 2018年06月29日 內容資訊: 英文 3034 Pages
簡介

非小細胞肺癌 (NSCLC) ,是的癌症(惡性腫瘤)。最常見的肺癌之一。是從肺的組織和呼吸道的細胞產生抽煙,是肺癌的最多原因。肺癌的症狀,通常發現已是後期。在徵兆與症狀上,有持續性咳嗽,呼吸困難,呼吸急促,恆常性的胸部疼痛和不舒服,醫血痰,疲勞,虛弱,不打算的體重減少等症狀。治療中,包含投藥、化療、生活風格的變更等。

本報告提供非小細胞肺癌的治療藥的開發情形對調查分析,開發中產品的概要,臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

非小細胞肺癌概要

治療藥的開發

非小細胞肺癌:企業開發中的治療藥

非小細胞肺癌:大學/機關研究中的治療藥

非小細胞肺癌:開發中產品概況

非小細胞肺癌:企業開發中的產品

非小細胞肺癌:大學/機關研究中的產品

非小細胞肺癌的治療藥的開發企業

非小細胞肺癌:治療藥的評估

藥物簡介

非小細胞肺癌:暫停中的計劃

非小細胞肺癌:開發中止的產品

非小細胞肺癌:產品開發的里程碑

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC10535IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Small Cell Lung Cancer - Pipeline Review, H1 2018, provides an overview of the Non-Small Cell Lung Cancer (Oncology) pipeline landscape.

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC is a cancer (malignancy) that originates in the tissues of the lungs or the cells lining the airways. Symptoms of lung cancer usually occur in later stages of the disease. The signs and symptoms include persistent cough that may get worse over time, trouble breathing or shortness of breath, constant chest pain or discomfort, bloody phlegm or spit (sputum), fatigue and weakness and unintentional weight loss. The disease might be controlled with the help of medications, chemotherapy and modifications in lifestyle.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non-Small Cell Lung Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Non-Small Cell Lung Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non-Small Cell Lung Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Non-Small Cell Lung Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 9, 1, 49, 238, 205, 16, 175, 30 and 14 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 13, 14, 46 and 5 molecules, respectively.

Non-Small Cell Lung Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Small Cell Lung Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Non-Small Cell Lung Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Non-Small Cell Lung Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Non-Small Cell Lung Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Non-Small Cell Lung Cancer (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Non-Small Cell Lung Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Non-Small Cell Lung Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Non-Small Cell Lung Cancer - Overview
  • Non-Small Cell Lung Cancer - Therapeutics Development
  • Non-Small Cell Lung Cancer - Therapeutics Assessment
  • Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development
  • Non-Small Cell Lung Cancer - Drug Profiles
  • Non-Small Cell Lung Cancer - Dormant Projects
  • Non-Small Cell Lung Cancer - Discontinued Products
  • Non-Small Cell Lung Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Non-Small Cell Lung Cancer, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by 3-V Biosciences Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by 3SBio Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by 4D Pharma PLC, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by 4SC AG, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by AbbVie Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Ability Pharmaceuticals SL, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Abpro, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by ACEA Biosciences Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Adamed Sp z oo, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Aduro BioTech Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Advantagene Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Advaxis Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Advenchen Laboratories LLC, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Agenus Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by AlfaSigma SpA, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Altimmune Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Altor BioScience Corp, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Amgen Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Andarix Pharmaceuticals Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by AndroScience Corp, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Apexigen Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Aptose Biosciences Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Arcus Biosciences Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Ariad Pharmaceuticals Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by ARMO Biosciences Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by ArQule Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Array BioPharma Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Asana BioSciences LLC, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Ascentage Pharma Group Corp Ltd, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Astellas Pharma Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Asterias Biotherapeutics Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by AstraZeneca Plc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Atreca Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Aurobindo Pharma Ltd, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by AVEO Pharmaceuticals Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Basilea Pharmaceutica Ltd, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Batu Biologics Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Bavarian Nordic A/S, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Bayer AG, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by BeiGene Ltd, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by BerGenBio ASA, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Beta Pharma Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Betta Pharmaceuticals Co Ltd, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by BeyondSpring Pharmaceuticals Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Bicycle Therapeutics Ltd, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Bio-Cancer Treatment International Ltd, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by BioAtla LLC, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Biocad, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by BioCancell Ltd, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Biocon Ltd, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by BioLineRx Ltd, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Biothera Pharmaceutical Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Blueprint Medicines Corp, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Boston Biomedical Inc, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by BriaCell Therapeutics Corp, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by BrightPath Biotherapeutics Co Ltd, H1 2018
  • Non-Small Cell Lung Cancer - Pipeline by Bristol-Myers Squibb Co, H1 2018

List of Figures

  • Number of Products under Development for Non-Small Cell Lung Cancer, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Top 10 Targets, H1 2018
  • Number of Products by Stage and Top 10 Targets, H1 2018
  • Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Top 10 Routes of Administration, H1 2018
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2018
  • Number of Products by Top 10 Molecule Types, H1 2018
  • Number of Products by Stage and Top 10 Molecule Types, H1 2018
Back to Top